GNLX (STOCKS)
Genelux Corporation Common Stock
$2.490000
+0.070000 (+2.89%)
Prev close: $2.420000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Thomas D. Zindrick
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $110.90M
- Employees
- 24
- P/E (TTM)
- -2.83
- P/B (TTM)
- 5.04
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.21 | $-0.22 | +0.0062 | +2.87% |
|
Jun 2025 (Q2)
|
$-0.20 | $-0.22 | +0.0193 | +8.80% |
|
Mar 2025 (Q1)
|
$-0.21 | $-0.25 | +0.0374 | +15.12% |
|
Dec 2024 (Q4)
|
$-0.26 | $-0.19 | -0.0738 | -39.63% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $1.68M |
| Operating Expenses | $33.55M |
| Research and Development | $20.72M |
| Other Operating Expenses | $12.83M |
| Operating Income/Loss | -$33.55M |
| Income/Loss From Continuing Operations After Tax | -$31.87M |
| Income/Loss From Continuing Operations Before Tax | -$2.00M |
| Net Income/Loss | -$31.87M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$31.87M |
| Net Income/Loss Available To Common Stockholders, Basic | -$31.87M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.88 |
| Diluted Earnings Per Share | -$0.88 |
| Basic Average Shares | 37,912,719 |
| Diluted Average Shares | 111,810,831 |
| Assets | $24.99M |
| Current Assets | $21.55M |
| Noncurrent Assets | $3.44M |
| Fixed Assets | $1.79M |
| Other Non-current Assets | $1.64M |
| Liabilities | $6.40M |
| Current Liabilities | $5.13M |
| Noncurrent Liabilities | $1.27M |
| Equity | $18.59M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $18.59M |
| Liabilities And Equity | $24.99M |
| Net Cash Flow From Operating Activities | -$23.37M |
| Net Cash Flow From Operating Activities, Continuing | -$23.37M |
| Net Cash Flow From Investing Activities | $12.25M |
| Net Cash Flow From Investing Activities, Continuing | $12.25M |
| Net Cash Flow From Financing Activities | $9.71M |
| Net Cash Flow From Financing Activities, Continuing | $9.71M |
| Net Cash Flow | -$1.41M |
| Net Cash Flow, Continuing | -$1.41M |
| Comprehensive Income/Loss | -$31.99M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$31.99M |
| Other Comprehensive Income/Loss | -$31.99M |